[15-12G] HOOKIPA Pharma Inc. SEC Filing

Rhea-AI Filing Summary

Analyzing...

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER

SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION

OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-38869

HOOKIPA Pharma Inc.

(Exact name of registrant as specified in its charter)

350 Fifth Avenue, 72nd Floor, Suite 7240

New York, NY 10118

+43 1 890 63 60

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

	Rule 12g-4(a)(1)	x
	Rule 12g-4(a)(2)	¨
	Rule 12h-3(b)(1)(i)	x
	Rule 12h-3(b)(1)(ii)	¨
	Rule 15d-6	¨
	Rule 15d-22(b)	¨

Approximate number of holders of record as of the certification or notice date: 56

Pursuant to the requirements of the Securities Exchange Act of 1934, HOOKIPA Pharma Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: August 8, 2025	By:	/s/ Malte Peters
	Name:	Malte Peters
	Title:	Chief Executive Officer